Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension; and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease. Its products also comprise FreeHold retractors that are minimally invasive surgical device solutions. The company has a strategic collaboration with Medtronic for the development and commercialization of BackBeat CNT for the treatment of hypertension in pacemaker-indicated patients; and a strategic partnership with Terumo Corporation for the development and commercialization of Virtue SAB for the treatment of artery disease. Orchestra BioMed Holdings, Inc. is based in New Hope, Pennsylvania.
Revenue of Orchestra BioMed Holdings, Inc. (OBIO)
Revenue in 2023 (TTM): $2.76 M
According to Orchestra BioMed Holdings, Inc.'s latest financial reports the company's current revenue (TTM) is $2.76 M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Orchestra BioMed Holdings, Inc.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $2.76 M | $2.43 M | $-51,219,000 | $-49,120,000 | $-49,120,000 |
| 2022 | $3.53 M | $3.21 M | $-32,435,000 | $-33,608,000 | $-33,608,000 |
| 2021 | $-782,000 | $-981,000 | $-21,618,000 | $-23,014,000 | $-23,014,000 |
| 2020 | $5.7 M | $5.56 M | $-15,681,000 | $-21,355,000 | $-21,355,000 |